Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
37,883,682

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests

Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.

Incyte (INCY) to Report Q4 Earnings: What's in the Offing?

Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.

Best Growth Stocks to Buy for February 3rd

CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 3, 2022

Nalak Das headshot

5 Corporate Bigwigs to Buy Ahead of Earnings Next Week

Five corporate bigwigs will report fourth-quarter 2021 earnings results next week. These are: HAS, PFE, TWLO, CDW and NLY.

Zacks.com featured highlights include: Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc

Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc are highlighted in this Screen of the Week article.

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Is a Beat Likely for Pfizer (PFE) This Earnings Season?

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Is a Beat Likely for Amgen (AMGN) This Earnings Season?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing

Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.

Sweta Killa headshot

5 Cheap Dividend Growth Stocks to Bet Amid Volatility

Pfizer (PFE), Kroger (KR), Archer-Daniels (ADM), HP Inc. (HPQ) and Jones Lang (JLL) seems compelling cheap picks amid volatility.

Best Growth Stocks to Buy for February 2nd

PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 2, 2022

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $53.07, marking a +0.72% move from the previous day.

Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod

The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.

Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab

After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.

Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis

Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.

Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.

Best Growth Stocks to Buy for February 1st

CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 1, 2022

Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel

Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.

Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?

Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.

Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer

The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.

Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema

While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.

AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery

AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.

Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?

Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

Best Growth Stocks to Buy for January 31st

PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2022